April 17, 2023 07:01 AM EDTUpdated 07:52 AM
R&D

GSK stopped two UTI an­tibi­ot­ic tri­als ear­ly af­ter meet­ing ef­fi­ca­cy end­points. Now it’s shar­ing the full da­ta

Lei Lei Wu

News Reporter

At a con­fer­ence in Copen­hagen, GSK shared the full da­ta on Sat­ur­day from two Phase III tri­als of its new an­tibi­ot­ic for uri­nary tract in­fec­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times